- Home
- BAND vs FHTX Comparison
BAND vs FHTX Comparison
Compare BAND & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAND | FHTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 332.2M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BAND | FHTX |
|---|---|---|
| Price | $20.42 | $4.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $20.40 | $11.50 |
| AVG Volume (30 Days) | ★ 359.0K | 131.7K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | $30,909,000.00 |
| Revenue This Year | $15.16 | $7.81 |
| Revenue Next Year | $6.18 | $17.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 36.75 |
| 52 Week Low | $11.33 | $3.27 |
| 52 Week High | $19.59 | $6.95 |
Technical Indicators
Market Signals| Indicator | BAND | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 46.58 |
| Support Level | $13.20 | $4.42 |
| Resistance Level | N/A | $5.85 |
| Average True Range (ATR) | 1.04 | 0.27 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 97.77 | 57.65 |
Price Performance
Historical ComparisonAbout BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.